Literature DB >> 7655882

Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group.

L H Visser1, F G Van der Meché, P A Van Doorn, J Meulstee, B C Jacobs, P G Oomes, R P Kleyweg, J Meulstee.   

Abstract

We analysed data obtained from 27 out of a group of 147 patients with Guillain-Barré syndrome, who did not have sensory loss during a follow-up period of 6 months (motor Guillain-Barré syndrome). These patients had a distinctive clinical pattern compared with the other 120 Guillain-Barré syndrome patients. The clinical course was marked by a more rapid onset of weakness (3.9 versus 6.1 days, P = 0.002), an earlier nadir (6.3 versus 9.1 days, P < 0.001), an initially predominant distal weakness (67% versus 27%, P < 0.001), sparing of the cranial nerves (26% versus 68%, P < 0.001) and the disease was more often preceded by a gastro-intestinal illness (41% versus 13%, P = 0.001) often caused by a Campylobacter jejuni infection (67% versus 28% in the other Guillain-Barré syndrome patients, P < 0.001). High titres of anti-GM1 antibodies were also significantly more common in motor Guillain-Barré syndrome patients (42% versus 5%, P < 0.001). Electromyographic data of the motor Guillain-Barré syndrome patients at nadir revealed little or no evidence for demyelination. Abundant denervation activity was present in half of the patients. The response to immune globulin treatment was good but with plasma exchange significantly fewer motor Guillain-Barré syndrome patients reached the stage of independent locomotion after a follow-up period of 6 months especially if the acute motor neuropathy occurred after a C.jejuni infection.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7655882     DOI: 10.1093/brain/118.4.841

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  17 in total

1.  Molecular characterization of Campylobacter jejuni from patients with Guillain-Barré and Miller Fisher syndromes.

Authors:  H P Endtz; C W Ang; N van Den Braak; B Duim; A Rigter; L J Price; D L Woodward; F G Rodgers; W M Johnson; J A Wagenaar; B C Jacobs; H A Verbrugh; A van Belkum
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Abstracts of the 13th Meeting of the European Neurological Society. 14-18 June 2003, Istanbul, Turkey.

Authors: 
Journal:  J Neurol       Date:  2003-05       Impact factor: 4.849

Review 3.  [Use of i.v. immunoglobulins in neurology. Evidence-based consensus].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2004-08       Impact factor: 1.214

Review 4.  Therapy of immune neuropathies with intravenous immunoglobulins.

Authors:  Ralf Gold; Bernd C Kieseier
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 5.  Clinical utility of autoantibodies in Guillain-Barre syndrome and its variants.

Authors:  J W Terryberry; Y Shoenfeld; J B Peter
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 6.  Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis.

Authors:  Bianca van den Berg; Christa Walgaard; Judith Drenthen; Christiaan Fokke; Bart C Jacobs; Pieter A van Doorn
Journal:  Nat Rev Neurol       Date:  2014-07-15       Impact factor: 42.937

Review 7.  Autoimmune responses in peripheral nerve.

Authors:  H P Hartung; H Willison; S Jung; M Pette; K V Toyka; G Giegerich
Journal:  Springer Semin Immunopathol       Date:  1996

8.  Epidemiological features of Guillain-Barré syndrome in Sweden, 1978-93.

Authors:  G X Jiang; Q Cheng; H Link; J de Pedro-Cuesta
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-05       Impact factor: 10.154

9.  Isolated absence of F waves and proximal axonal dysfunction in Guillain-Barré syndrome with antiganglioside antibodies.

Authors:  S Kuwabara; K Ogawara; K Mizobuchi; M Koga; M Mori; T Hattori; N Yuki
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-02       Impact factor: 10.154

10.  Recovery patterns and long term prognosis for axonal Guillain-Barré syndrome.

Authors:  A Hiraga; M Mori; K Ogawara; S Kojima; T Kanesaka; S Misawa; T Hattori; S Kuwabara
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-05       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.